Background Gastric cancer (GC) is the second most common cause of cancer-related death worldwide. Novel anticancer drugs against gastric cancer are urgently needed. Methods Compound 10 was designed and synthesized via a molecular hybridization strategy based on the natural product formononetin. It was evaluated for their antiproliferative activity against three gastric cancer cell lines (SGC7901, MKN45 and MGC803). Results Derivative 10 displayed potently antiproliferative activity with an IC50 value of 1.07 μM against SGC7901 cells. Derivative 10 could inhibit the growth and migration against gastric cancer SGC7901 cells through the Wnt/β-Catenin and AKT/mTOR pathways. From the in vivo expremints, it could effectively inhibited SGC7901 xenograft tumor growth in vivo without significant loss of the body weight. Conclusion Derivative 10 is an novel antitumor agent with potential for further clinical applications to treat gastric cancer.
背景 胃癌(GC)是全球第二大最常见的癌症致死原因。针对胃癌的新型抗癌药物亟待开发。方法 基于
天然产物甲壬素,通过分子杂交策略设计并合成了化合物 10。评估了其对三种胃癌
细胞系(SGC7901、MKN45 和 MGC803)的抗增殖活性。结果 衍
生物 10 对 SGC7901 细胞具有强效的抗增殖活性,IC50 值为 1.07 μM。衍
生物 10 可通过 Wnt/β-Catenin 和 AKT/mTOR 通路抑制胃癌 SGC7901 细胞的生长和迁移。从体内试验来看,它能有效抑制 SGC7901 异种移植瘤在体内的生长,且体重无明显减轻。结论 衍
生物 10 是一种新型
抗肿瘤药物,具有进一步应用于临床治疗胃癌的潜力。